NCLAT: Consideration of Debt Restructuring by Lenders Doesn’t Bar Member from Initiating Proceedings  ||  Delhi High Court: In Matters of Medical Evaluation, Courts Should Exercise Restraint  ||  Delhi HC: Any Person in India Has Right to Legally Import Goods from Abroad and Sell the Same  ||  Delhi HC: Waiver to Section 12(5) of Arbitration Act to be Given Once Tribunal is Constituted  ||  Supreme Court Has Asked States to Regularise Existing Court Managers  ||  SC: Union & States to Create Special POSCO Courts on Top Priority  ||  SC Upholds Authority of CERC to Award Compensation for Delays  ||  SC: Arbitral Tribunal Has Discretion to Include in Sum Awarded, Interest at Rate as it Deems Reasonab  ||  SC: Cannot Use Article 142 to Frame Guidelines on Judicial Recusal  ||  SC: Satisfaction Recorder in One EP Won’t Affect Subsequent EPs for Future Breaches    

Indian Patent Office Disallows Patent for Boehringer Ingelheim’s HIV Drug, Nevirapine - (21 Oct 2015)

Indian Patent Office has disallowed Germany's Boehringer Ingelheim a patent on its HIV drug, Nevirapine, sold as Viramune XR (extended release), yet again thwarting attempts by Big Pharma for "exclusivity" extension on their patented drugs to reportedly block entry of affordable generics.

Tags : BOEHRINGER INGELHEIM   PATENT   HIV DRUG   NEVIRAPINE  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved